Brain tumor

EndBrainCancer Initiative to Join National Brain Tumor Society, American Brain Tumor Society, and the Ivy Center at Barrow Neurological Institute to "Shine a Light" on the Deadliest Type of Brain Cancer

Retrieved on: 
Monday, June 21, 2021
National Brain Tumor Society, Brain tumor, Green Belt Movement

We are encouraging all members of the brain tumor community to come together in a Virtual Town Hall on July 21.

Key Points: 
  • We are encouraging all members of the brain tumor community to come together in a Virtual Town Hall on July 21.
  • According to the EndBrainCancer Initiative, GBM Awareness Day represents an opportunity to raise national consciousness about everyone's stake in finding a cure for this disease.
  • Audience generation activities to encourage people to sign up and raise their voice in the National Brain Tumor Society (NBTS) live Virtual Town Hall.
  • EBCI President & Chair, Dellann Elliott Mydland has this to say about National GBM Day:"The EndBrainCancer Initiative and I are honored and excited to participate in this very important national awareness initiative.

Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight

Retrieved on: 
Wednesday, June 16, 2021
Research, Publishing, Genetics, Clinical trials, Communications, Biotechnology, Pharmaceutical, Health, Science, Oncology, Brain tumor, Aging-associated diseases, Cancer, Health, Clinical medicine, Oncology, Brain metastasis, Blastoma, Glioblastoma

Patrys Limited (ASX:PAB), a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic antibody candidate PAT-DX1 in The Journal of Clinical InvestigationInsight.

Key Points: 
  • Patrys Limited (ASX:PAB), a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic antibody candidate PAT-DX1 in The Journal of Clinical InvestigationInsight.
  • Patrys is developing PAT-DX1 for use in DDR-deficient cancers, including a range of primary brain cancers and metastases.
  • Glioblastoma and TNBC brain metastases are very difficult to treat, and the prognosis for patients with these cancers is generally poor.
  • For more information about Patrys, please visit www.patrys.com and follow us on Twitter (@PatrysLtd) and LinkedIn.

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

Retrieved on: 
Tuesday, June 15, 2021
Health, Oncology, Medicine, Metabolism, Brain tumor, Drug discovery, Cancer, Glioblastoma, Ketosis, Phosphoinositide 3-kinase, Ketogenic diet, Clinical trial

Our research clearly shows the synergistic benefits of PI3K inhibition and ketosis in animal models of glioblastoma.

Key Points: 
  • Our research clearly shows the synergistic benefits of PI3K inhibition and ketosis in animal models of glioblastoma.
  • For these reasons, there is a sound rationale to explore a combination of ketogenic diet and paxalisib in glioblastoma.
  • The diet will be overseen by expert clinical dieticians to ensure that it is scientifically appropriate and that patients are compliant.
  • The initiation of this trial in glioblastoma brings the number of ongoing clinical studies of paxalisib in brain cancer to nine.

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

Retrieved on: 
Thursday, June 10, 2021
Health, Brain tumor, Cancer, Glioblastoma, Oncology, Clinical medicine, Medicine

AUSTIN, Texas, June 10, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6 th Biennial Pediatric Neuro-Oncology Research Conference hosted by the Society for Neuro-Oncology (SNO), being held virtually June 10-12, 2021.

Key Points: 
  • AUSTIN, Texas, June 10, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6 th Biennial Pediatric Neuro-Oncology Research Conference hosted by the Society for Neuro-Oncology (SNO), being held virtually June 10-12, 2021.
  • A copy of the poster is available under the Presentations tab of the Investors section of the Companys website.
  • Presented data include a review of relevant preclinical research, the companys Phase 1 ReSPECTTM clinical trial in recurrent glioblastoma (GBM) and a proposed design for initiating a Phase I clinical trial in pediatric brain tumors.
  • Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.

VBI Vaccines Announces Results of Annual General Meeting

Retrieved on: 
Wednesday, June 9, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medicine, Medical specialties, Health, Betaherpesvirinae, Viral diseases, Brain tumor, Cancer, Glioblastoma, Coronavirus, Cytomegalovirus, Variation Biotechnologies

Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company's SEC and SEDAR filings.

Key Points: 
  • Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company's SEC and SEDAR filings.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Navigation Sciences™ Begins First-in-Human Clinical Feasibility Trial of its Pioneering, NaviSci™ System for Tissue-Conserving Removal of Early-Stage Lung Tumors

Retrieved on: 
Wednesday, June 9, 2021
Oncology, Health, Medical devices, Technology, Surgery, Software, Clinical trials, Lung cancer, Cancer, Brain tumor, Health, Microwave ablation

Navigation Sciences today announced that the initial patient has participated in the first-in-human clinical feasibility trial of its NaviSci System for use in minimally invasive surgery to remove probable early-stage lung tumors.

Key Points: 
  • Navigation Sciences today announced that the initial patient has participated in the first-in-human clinical feasibility trial of its NaviSci System for use in minimally invasive surgery to remove probable early-stage lung tumors.
  • The clinical trial marks an important milestone for the NaviSci Systems development and the company, said Alan D. Lucas, co-founder, and CEO of Navigation Sciences.
  • There are more than 225,000 new cases of lung cancer diagnosed in the U.S. annually, of which more than 76,000 are early-stage tumors.
  • Navigation Sciences is a clinical-stage company developing the NaviSci System for the tissue conserving removal of lung cancer and other soft tissue tumors.

VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM

Retrieved on: 
Tuesday, June 8, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Research, Infectious diseases, Science, Clinical trials, Health, Brain tumor, Cancer, Glioblastoma, Oncology, Fast track, Causes of death, Life sciences, Fast Track Designation, VBI-1901 and GBM, VBI Vaccines Inc., FAST TRACK DESIGNATION, VBI-1901 AND GBM, VBI VACCINES INC.

VBI Vaccines Inc. ( Nasdaq: VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for VBI-1901, VBIs cancer vaccine immunotherapeutic candidate for the treatment of recurrent glioblastoma (GBM) patients with first tumor recurrence.

Key Points: 
  • VBI Vaccines Inc. ( Nasdaq: VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for VBI-1901, VBIs cancer vaccine immunotherapeutic candidate for the treatment of recurrent glioblastoma (GBM) patients with first tumor recurrence.
  • Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need.
  • Fast Track Designation was granted to VBI-1901, adjuvanted with granulocyte macrophage colony-stimulating factor (GM-CSF), for the treatment of first-recurrent GBM.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

DGAP-News: MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications

Retrieved on: 
Monday, June 7, 2021
Cancer, Health, Brain tumor, Pediatric cancers, Clinical medicine, Oncology, Glioblastoma, Blastoma, MagForce, World Brain Tumor Day, MagForce AG and MagForce USA, Inc., WORLD BRAIN TUMOR DAY, MAGFORCE AG AND MAGFORCE USA, INC.

"Though rare compared to other types of cancers, brain tumors, especially glioblastomas, are a devastating and mostly fatal disease.

Key Points: 
  • "Though rare compared to other types of cancers, brain tumors, especially glioblastomas, are a devastating and mostly fatal disease.
  • Despite major advances in treatment modalities, malignant tumors of the brain remain largely incurable and an unresolved therapeutic problem.
  • On occasion of the 2021 World Brain Tumor Day, the SPSK4 will host a free Infoline, supported by MagForce and Alivia Cancer Foundation.
  • MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

Ivy Brain Tumor Center Announces Interim Results from a Phase 0 ‘Trigger’ Trial of Targeted Combination Therapy for Glioblastoma

Retrieved on: 
Friday, June 4, 2021
Health sciences, Chemical compounds, Health, Breakthrough therapy, Piperazines, Protein kinase inhibitors, Brain tumor, Abemaciclib, Clinical trial, University of Miami Division of Surgical Neurooncology, Atypical teratoid rhabdoid tumor

In this ongoing Phase 0 study, patients receive six days of abemaciclib in combination with LY3214996 leading up to a timed brain tumor resection following the final dose.

Key Points: 
  • In this ongoing Phase 0 study, patients receive six days of abemaciclib in combination with LY3214996 leading up to a timed brain tumor resection following the final dose.
  • To date, 19 patients have enrolled in this Phase 0 clinical trial and six patients have advanced to Phase 2.
  • Additional clinical trial information can be found at NCT04391595 or the Ivy Brain Tumor Centers website .
  • Follow the Ivy Brain Tumor Center on Facebook , Instagram , Twitter and LinkedIn .

Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

Retrieved on: 
Friday, June 4, 2021
Brain tumor, Neuroblastoma, Cancer, Ontology, Types

The three-year event free survival (EFS) for patients in first CR was 74% and 19% for second or later CR.

Key Points: 
  • The three-year event free survival (EFS) for patients in first CR was 74% and 19% for second or later CR.
  • The three-year overall survival (OS) for the patients in first CR was 92% and 66% for second or later CR patients.
  • We are very pleased to report such encouraging three-year follow-up data in frontline high-risk neuroblastoma for DANYELZA in patients that are in full remission after the induction regiment, stated Thomas Gad, founder, Chairman and President.
  • Dr. Claus Moller, Chief Executive Officer, continued, We are excited to see the three-year data holding up so well for the frontline patients and, if approved, we believe this could potentially significantly differentiate DANYELZA from other existing therapies.